Scott Giacobello's most recent trade in Whitehawk Therapeutics Inc. was a trade of 38,265 Common Stock done at an average price of $3.9 . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 3.92 per share. | 14 May 2026 | 38,265 | 333,489 | - | 3.9 | 149,999 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.13 per share. | 15 Apr 2026 | 141,600 | 295,224 | - | 4.1 | 584,808 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 3.86 per share. | 15 Apr 2026 | 77,000 | 436,824 | - | 3.9 | 297,220 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 473,902 | 502,002 | - | - | Common Stock | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 473,902 | 0 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 300,677 | 300,677 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 6,750 | 30,694 | - | - | Common Stock | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 6,750 | 13,500 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 3.31 per share. | 01 Mar 2026 | 2,594 | 28,100 | - | 3.3 | 8,585 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 473,902 | 473,902 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 473,902 | 473,902 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,750 | 26,750 | - | - | Common Stock | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,750 | 20,250 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 2.35 per share. | 01 Mar 2025 | 2,806 | 23,944 | - | 2.3 | 6,594 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 138,263 | 138,263 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 27,000 | 27,000 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CFO, Interim CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 90,000 | 90,000 | - | - | Stock option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.50 per share. | 26 Sep 2022 | 20,000 | 20,000 | - | 12.5 | 250,000 | Common Stock |
| Whitehawk Therapeutics Inc | Scott Giacobello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 46,400 | 46,400 | - | - | Stock option (right to buy) |